173 related articles for article (PubMed ID: 30529990)
1. Impact of timing of administration of bone supportive therapy on pain palliation from radium-223.
Yap KK; Wong W; Ji L; Groshen S; Quinn DI; Bryce AH; Dorff TB
Cancer Treat Res Commun; 2019; 18():100114. PubMed ID: 30529990
[TBL] [Abstract][Full Text] [Related]
2. Concurrent or layered treatment with radium-223 and enzalutamide or abiraterone/prednisone: real-world clinical outcomes in patients with metastatic castration-resistant prostate cancer.
Shore N; Higano CS; George DJ; Sternberg CN; Saad F; Tombal B; Miller K; Kalinovsky J; Jiao X; Tangirala K; Sartor O
Prostate Cancer Prostatic Dis; 2020 Dec; 23(4):680-688. PubMed ID: 32404868
[TBL] [Abstract][Full Text] [Related]
3. The role of bisphosphonates or denosumab in light of the availability of new therapies for prostate cancer.
Saad F; Sternberg CN; Mulders PFA; Niepel D; Tombal BF
Cancer Treat Rev; 2018 Jul; 68():25-37. PubMed ID: 29787892
[TBL] [Abstract][Full Text] [Related]
4. Radium-223 and concomitant therapies in patients with metastatic castration-resistant prostate cancer: an international, early access, open-label, single-arm phase 3b trial.
Saad F; Carles J; Gillessen S; Heidenreich A; Heinrich D; Gratt J; Lévy J; Miller K; Nilsson S; Petrenciuc O; Tucci M; Wirth M; Federhofer J; O'Sullivan JM;
Lancet Oncol; 2016 Sep; 17(9):1306-16. PubMed ID: 27473888
[TBL] [Abstract][Full Text] [Related]
5. Treatment of Metastatic Castration-resistant Prostate Cancer With Abiraterone and Enzalutamide Despite PSA Progression.
Becker DJ; Iyengar AD; Punekar SR; Ng J; Zaman A; Loeb S; Becker KD; Makarov D
Anticancer Res; 2019 May; 39(5):2467-2473. PubMed ID: 31092441
[TBL] [Abstract][Full Text] [Related]
6. Radionuclide Therapies in Prostate Cancer: Integrating Radium-223 in the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer.
Nilsson S
Curr Oncol Rep; 2016 Feb; 18(2):14. PubMed ID: 26779616
[TBL] [Abstract][Full Text] [Related]
7. Abiraterone Followed by Enzalutamide Versus Enzalutamide Followed by Abiraterone in Chemotherapy-naive Patients With Metastatic Castration-resistant Prostate Cancer.
Matsubara N; Yamada Y; Tabata KI; Satoh T; Kamiya N; Suzuki H; Kawahara T; Uemura H; Yano A; Kawakami S; Otsuka M; Fukasawa S
Clin Genitourin Cancer; 2018 Apr; 16(2):142-148. PubMed ID: 29042308
[TBL] [Abstract][Full Text] [Related]
8. Quality of life in patients with metastatic prostate cancer following treatment with cabazitaxel versus abiraterone or enzalutamide (CARD): an analysis of a randomised, multicentre, open-label, phase 4 study.
Fizazi K; Kramer G; Eymard JC; Sternberg CN; de Bono J; Castellano D; Tombal B; Wülfing C; Liontos M; Carles J; Iacovelli R; Melichar B; Sverrisdóttir Á; Theodore C; Feyerabend S; Helissey C; Oudard S; Facchini G; Poole EM; Ozatilgan A; Geffriaud-Ricouard C; Bensfia S; de Wit R
Lancet Oncol; 2020 Nov; 21(11):1513-1525. PubMed ID: 32926841
[TBL] [Abstract][Full Text] [Related]
9. Safety of concomitant therapy with radium-223 and abiraterone or enzalutamide in a real-world population.
Zhao H; Howard LE; De Hoedt AM; Terris MK; Amling CL; Kane CJ; Cooperberg MR; Aronson WJ; Klaassen Z; Polascik TJ; Vidal AC; Freedland SJ
Prostate; 2021 May; 81(7):390-397. PubMed ID: 33705584
[TBL] [Abstract][Full Text] [Related]
10. Effects of six-cycle completion and earlier use of radium-223 therapy on prognosis for metastatic castration-resistant prostate cancer: A real-world multicenter retrospective study.
Sasaki D; Hatakeyama S; Kawaguchi H; Hatayama Y; Ishibashi Y; Kusaka A; Noro D; Tanaka T; Ito H; Okuyama Y; Okamoto T; Yamamoto H; Yoneyama T; Hashimoto Y; Aoki M; Ohyama C
Urol Oncol; 2022 Feb; 40(2):64.e1-64.e8. PubMed ID: 34973857
[TBL] [Abstract][Full Text] [Related]
11. A single arm phase II study of bone-targeted Sn-117 m-DTPA in symptomatic castration-resistant prostate cancer with skeletal metastases.
Myint ZW; El Khouli R; Lemieux B; Yan D; St Clair WH; Liu X; Kunos CA
BMC Cancer; 2022 Apr; 22(1):415. PubMed ID: 35428207
[TBL] [Abstract][Full Text] [Related]
12. Radium-223 (Xofigo) with concurrent abiraterone or enzalutamide: predictive biomarkers of improved overall survival in a clinically advanced cohort.
Rathbun JT; Franklin GE
Curr Probl Cancer; 2019 Jun; 43(3):205-212. PubMed ID: 29983206
[TBL] [Abstract][Full Text] [Related]
13. [Radium-223 dichloride in patients with castration-refractory prostate cancer].
Winter BM; von Rundstedt FC; Grimm MO
Urologe A; 2017 Nov; 56(11):1435-1439. PubMed ID: 29022046
[TBL] [Abstract][Full Text] [Related]
14. Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial.
Smith M; Parker C; Saad F; Miller K; Tombal B; Ng QS; Boegemann M; Matveev V; Piulats JM; Zucca LE; Karyakin O; Kimura G; Matsubara N; Nahas WC; Nolè F; Rosenbaum E; Heidenreich A; Kakehi Y; Zhang A; Krissel H; Teufel M; Shen J; Wagner V; Higano C
Lancet Oncol; 2019 Mar; 20(3):408-419. PubMed ID: 30738780
[TBL] [Abstract][Full Text] [Related]
15. Immune Analysis of Radium-223 in Patients With Metastatic Prostate Cancer.
Kim JW; Shin MS; Kang Y; Kang I; Petrylak DP
Clin Genitourin Cancer; 2018 Apr; 16(2):e469-e476. PubMed ID: 29137877
[TBL] [Abstract][Full Text] [Related]
16. Clinical response to radium-223 dichloride in men with metastatic castrate-resistant prostate cancer.
Zhang I; Gilbo P; Kohn N; Cox B
Pract Radiat Oncol; 2018; 8(6):452-457. PubMed ID: 29934137
[TBL] [Abstract][Full Text] [Related]
17. Effect of enzalutamide on time to first skeletal-related event, pain, and quality of life in men with castration-resistant prostate cancer: results from the randomised, phase 3 AFFIRM trial.
Fizazi K; Scher HI; Miller K; Basch E; Sternberg CN; Cella D; Forer D; Hirmand M; de Bono JS
Lancet Oncol; 2014 Sep; 15(10):1147-56. PubMed ID: 25104109
[TBL] [Abstract][Full Text] [Related]
18. Hematologic Toxicity of Concurrent Administration of Radium-223 and Next-generation Antiandrogen Therapies.
Dan TD; Eldredge-Hindy HB; Hoffman-Censits J; Lin J; Kelly WK; Gomella LG; Lallas CD; Trabulsi EJ; Hurwitz MD; Dicker AP; Den RB
Am J Clin Oncol; 2017 Aug; 40(4):342-347. PubMed ID: 25723740
[TBL] [Abstract][Full Text] [Related]
19. Pain response in a population-based study of radium-223 (Ra223) for metastatic castration-resistant prostate cancer.
Parimi S; Bondy S; Tsang E; McKenzie MR; Bachand F; Aparicio M; Duncan G; Sunderland K; Olson RA; Pai HH; Alexander AS; LaPointe V; Chi KN; Tyldesley S
Can Urol Assoc J; 2019 Oct; 13(10):E311-E316. PubMed ID: 31364977
[TBL] [Abstract][Full Text] [Related]
20. Prospective Evaluation of Bone Metabolic Markers as Surrogate Markers of Response to Radium-223 Therapy in Metastatic Castration-resistant Prostate Cancer.
Agarwal N; Nussenzveig R; Hahn AW; Hoffman JM; Morton K; Gupta S; Batten J; Thorley J; Hawks J; Santos VS; Nachaegari G; Wang X; Boucher K; Haaland B; Maughan BL
Clin Cancer Res; 2020 May; 26(9):2104-2110. PubMed ID: 31937614
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
